| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 19,990 | 26,195 | 15,388 | 16,868 |
| Impairment of long-lived assets to be disposed of | - | - | - | 1,562 |
| Research and development | 8,112 | 10,490 | 11,452 | 9,268 |
| Selling, general and administrative | 18,333 | 18,430 | 18,370 | 16,875 |
| Total expenses | 26,445 | 28,920 | 29,822 | 27,705 |
| Loss from operations | -6,455 | -2,725 | -14,434 | -10,837 |
| Interest expense (non-cash) | 573 | 663 | 643 | 630 |
| Net gain on realized contingent milestone and royalty assets | - | 75,137 | - | - |
| Interest and other income, net | 4,139 | 1,457 | 939 | 1,415 |
| Income (loss) before income taxes | -2,889 | 73,206 | -14,138 | -10,052 |
| Provision for income tax benefit (expense) | -6,504 | 18,371 | -559 | 2,646 |
| Net income (loss) | 3,615 | 54,835 | -13,579 | -12,698 |
| Net unrealized gain on available-for-sale investments | 42 | -10 | -7 | 72 |
| Total comprehensive income (loss) | 3,657 | 54,825 | -13,586 | -12,626 |
| Earnings per share, basic | 0.07 | 1.09 | -0.27 | -0.26 |
| Earnings per share, diluted | 0.07 | 1.08 | -0.27 | -0.26 |
| Weighted average number of shares outstanding, basic | 50,520,000 | 50,177,000 | 49,706,000 | 49,038,000 |
| Weighted average number of shares outstanding, diluted | 51,908,000 | 50,726,000 | 49,706,000 | 49,038,000 |
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)